• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » N-acetylcysteine Shows Promise for Skin-Picking Disorder

N-acetylcysteine Shows Promise for Skin-Picking Disorder

July 1, 2016
Bret A. Moore, PsyD, ABPP
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
bret-a-moore-psyd-abppBret A. Moore, PsyD, ABPP Board-Certified Clinical Psychologist, San Antonio, TX Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Subject: (Grant J et al, JAMA Psychiatry, 2016;73:490–496)

Short Description: Excoriation, or what’s often referred to as skin-picking disorder (SPD), is a distressing and disfiguring behavior that affects up to 5% of people, occurring more commonly in women. Various lines of evidence imply that this compulsive behavior may be related to reduced levels of glutamate in the nucleus accumbens. N-acetylcysteine is an antioxidant that increases glutamate, and studies have shown that it is effective for excoriation’s sister disorder, trichotillomania (hair pulling). These data prompted investigators to try N-acetylcysteine in the treatment of SPD.

Over a 12-week period, 66 adult SPD patients from two Midwestern university-based clinics were randomized in a double-blind study to receive N-acetylcysteine (n=35) or placebo (n=31). The N-acetylcysteine group received 1,200 mg/day to start, increased to 2,400 mg/day by week three, and 3,000 mg/day by week six. An excoriation-specific version of the Yale-Brown Obsessive Compulsive Scale (NE-YBOCS) was used to assess picking symptoms over the three months. Researchers also used the Clinical Global Impression-Severity scale and other self-report, subjective measures.

The N-acetylcysteine seemed to work. Baseline NE-YBOCS scores dropped from 18.9 to 11.5 for the treatment group by the end of 12 weeks. During the same time period, the placebo scores shifted from 17.9 to 14.1. Subjective self-reports by the patients were also strong. Of the 53 patients who completed the study, 47% of the N-acetylcysteine group felt they were “much” or “very much” improved compared to only 19% of the placebo group. No significant adverse events were noted.

TCPR’s Take: The study was small, but given the benign side effect profile of N-acetylcysteine, it’s worth trying for patients with SPD.
General Psychiatry
KEYWORDS ocd research-update
    Bret a moore psyd abpp
    Bret A. Moore, PsyD, ABPP

    Extended-Release Guanfacine Improves ADHD Symptoms in Autism

    More from this author
    www.thecarlatreport.com
    Issue Date: July 1, 2016
    SUBSCRIBE NOW
    Table Of Contents
    Metoclopramide Helps Clozapine-Related Drooling
    N-acetylcysteine Shows Promise for Skin-Picking Disorder
    Buprenorphine for Suicidality? Maybe
    Citalopram Safety Warning Has Serious Consequences for VA Patients
    Take The CME Test For Medication in Pregnancy, TCPR, July/August 2016
    How to Evaluate and Treat Mood Disorders in Pregnancy
    What’s New with the FDA Labeling for Pregnancy and Lactation?
    Assessing Illness and Medication Treatment in the Perinatal Period
    DOWNLOAD NOW
    Featured Book
    • MFB6eCover.jpg

      Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

      Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto22709844.jpg
      General Psychiatry

      Psychopharm Commandment #10: Don’t Fear these Meds

      Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.